

# **· 냉각 결정화 기술의 응용전략-1**

# 고려대 화공생명공학과 양대륙



- 결정화 서론
  - ▶ 화학산업과 결정화
  - > 결정화 개요
  - > 결정화의 장점
- 냉각결정화 기본현상
  - ▶ 핵생성/ 성장
  - > 준안정영역
  - ▶ 핵생성 및 성장에 대한 중요변수
  - > 준안정영역 모델
- 결정화 Modeling
  - PBE model
  - Crystallization applet
- 최적냉각곡선
  - Natural/Linear/Optimal cooling
  - Optimization
- Process Analytical Technology (PAT)의 응용





# 서론



## • 화학제품의 분류 (Pollak, 1993)

|     | Commodities  | Fine chemicals  | Specialty Chemicals  |
|-----|--|---|--|
| 종류  | Petrochemicals<br>Basic chemicals<br>Large-volume organics<br>Monomers<br>Commodity fibers<br>Plastics | Advanced intermediates<br>Building blocks<br>Bulk drugs<br>Bulk pesticides<br>Active ingredients<br>Bulk vitamins<br>Amino acids<br>Flavor and fragrance<br>chemicals | Adhesives<br>Diagnostics<br>Disinfectants<br>Electronic chemicals<br>Food additives<br>Mining chemicals<br>Pesticides<br>Pharmaceuticals<br>Photographic chemicals<br>Specialty polymers<br>Water treatment<br>chemicals |
| 생산량 | >10,000 ton/yr   | 1–10,000 ton/yr   | <1 ton/yr  |
| 가격  | <\$2.5/kg  | \$2.5/kg-\$100/kg   | >\$100/kg  |
| 특징  | "what they are"  | "what they are"   | "What they can do"   |
| 수요처 | Industry   | Industry  | Public   |



# • 제품군에 따른 특징 (예)

#### Table 1. Comparison of Chemical Classes

| Parameter               | Com                 | modities                                     | Fine of                                    | hemicals  | Specialties     |  |
|-------------------------|---------------------|--|--|---|-----------------|--|
| example                 | o-xylene            | phthalic<br>anhydride                        | 3-amino-2-carboxy-4-<br>chlorobenzophenone | 2-chloro-5-(1-hydroxy-3-<br>oxo-1-isoindolinyl)<br>benzenesulfonamide | chlorthalidoneª |  |
| CAS Registry Number     | [95-47-6]           | [85-44-9]                                    |  | [77-36-1]   | [77-36-1]       |  |
| molecular formula       | C8H10               | C <sub>8</sub> H <sub>4</sub> O <sub>3</sub> | C14H10NO3Cl                                | C14H11CIN2O4S   | C14H11CIN2O4S   |  |
| applications            | >20                 | >10  | 1  | 1   | 1               |  |
| price level, \$/kg      | 0.50                | 1  | 10   | 100   | 1000            |  |
| production, t/yr        | $2.5 \times 10^{6}$ | $>1 \times 10^{6}$                           | 100  | 100   | 100             |  |
| producers               | 100                 | 25   | 1  | 1   | 1               |  |
| customers               | 100                 | 50   | 1  | captive   | >> consumers    |  |
| plant type <sup>b</sup> | D, C                | D, C   | М, В                                       | M, B  | F               |  |
| manufacturing steps     | 1                   | 2  | 5  | 10  | 1               |  |

<sup>a</sup>Also sold under the trade names Hydroton, Regroton, Igrolina, Igroton, and Renon. <sup>b</sup>B is batch; C, continuous; D, dedicated; M, multipurpose; and F, formulation.



# 화학산업의 특징

Table 1. The chemical sector-main characteristics of the industries

| Industry characteristics           | Bulk chemicals      | Fine chemicals      | Speciality chemicals  |
|------------------------------------|---------------------|---------------------|-----------------------|
| Product life cycle <sup>a</sup>    | Long                | Moderate            | Short/moderate        |
| Product range (number of products) | 00's                | 000's               | 0 000's               |
| Product volumes*                   | >10 000 t/y         | <10 000 t/y         | Highly variable       |
| Product prices <sup>a</sup>        | <5 US\$/kg          | >5 US\$/kg          | >5 US\$/kg            |
| Product differentiation            | None                | Very low            | High                  |
| Valued added                       | Low                 | High                | High                  |
| Capital intensity                  | High                | Moderate            | Moderate/low          |
| R&D focus                          | Process improvement | Process development | Application/product   |
| Key success factors <sup>b</sup>   | • • • • • •         |                     | , pp. out.on, product |
| -cost position                     | XXX                 | XX                  | х                     |
| -technical service                 | 1000 and 1000 - 20  | XX                  | xxx                   |
| -close links with the customer     | _                   | XXX                 | XXX                   |

\* Typical examples—exceptions may apply.

<sup>b</sup> Relative importance: X low; XX, average; XXX, high importance.



## • World most selling drugs

Source: IMS Health, a health care information company. Twelve months ending December 2005

|   | Drug<br>Name        | Sales<br>volume<br>(billion \$) | Annual<br>Growth<br>(%) | Usage            | Producer                                    |  |
|---|---------------------|---------------------------------|-------------------------|------------------|---|--|
| 1 | LIPITOR             | 12.9                            | 6.4                     | High cholesterol | Pfizer                                      |  |
| 2 | PLAVIX              | 5.9                             | 16.0                    | Heart disease    | Bristol-Myers<br>Squibb &<br>Sanofi-Aventis | en e |
| 3 | NEXIUM              | 5.7                             | 16.7                    | Heartburn        | AstraZeneca                                 |  |
| 4 | SERETIDE<br>/ADVAIR | 5.6                             | 19.0                    | Asthma           | GlaxoSmithKline                             |  |



|    |         | Drug<br>Name | Sales<br>volume<br>(billion \$) | Annual<br>Growth<br>(%) | Usage                  | Producer                      |                  |
|----|---------|--------------|---------------------------------|-------------------------|------------------------|-------------------------------|------------------|
|    | 5       | ZOCOR        | 5.3                             | -10.7                   | High cholesterol       | Merck                         |                  |
|    | 6       | NORVASC      | 5.0                             | 2.5                     | High blood<br>pressure | Pfizer                        | NIO<br>GRANS     |
|    | 7       | ZYPREXA      | 4.7                             | -6.8                    | Schizophrenia          | Eli Lilly                     |                  |
|    | 8       | RISPERDAL    | 4.0                             | 12.6                    | Schizophrenia          | Johnson &<br>Johnson          | RIJ              |
|    | 9       | PREVACID     | 4.0                             | 0.9                     | Heartburn              | Abbott Labs &<br>Takeda Pharm | PRE VE Y BUC PRE |
| 제유 | 10<br>• | EFFECXOR     | 3.8                             | 1.2                     | Depression             | Wyeth                         | 781              |

----

# • 세계의 제약회사 (2004)

| 순위 | 회사명                  | 국가          | 연간 매출<br>(MM\$) | R&D 투자비<br>(MM\$) | 순이익<br>(MM\$) | 종업원수    |
|----|----------------------|-------------|-----------------|-------------------|---------------|---------|
| 1  | Pfizer               | USA         | 52,516          | 7,684             | 11,361        | 115,000 |
| 2  | Johnson & Johnson    | USA         | 47,348          | 5,203             | 8,509         | 109,900 |
| 3  | GlaxoSmithKline      | UK          | 37,318          | 5,204             | 7,886         | 100,619 |
| 4  | Sanofi-Aventis       | France      | 31,615          | 4,927             | 6,526         | 96,439  |
| 5  | Novartis             | Switzerland | 28,247          | 4,207             | 5,767         | 81,392  |
| 6  | Hoffmann-La Roche    | Switzerland | 25,163          | 4,098             | 5,344         | 64,703  |
| 7  | Merck & Co.          | USA         | 22,939          | 4,010             | 5,813         | 62,600  |
| 8  | AstraZeneca          | UK          | 21,427          | 3,803             | 3,813         | 64,200  |
| 9  | Abbott Laboratories  | USA         | 19,680          | 1,697             | 3,236         | 50,600  |
| 10 | Bristol-Myers Squibb | USA         | 19,380          | 2,500             | 2,388         | 43,000  |



# • 페니실린 정제공정의 예






Fig. 3.7. Penicillin purification process of Gist-Brocades. (From Hersbach et al. 1984.)

#### 결정화란 (Crystallization)

분리기술의 일종으로 액체 혹은 기체의 균일상으로부터 조작을 통하 여 고체입자, 즉 결정(Crystal)을 얻는 과정


#### • 결정 (Crystal)

일정한 각도로 교차하는 평면이 대칭적으로 정렬된 특징적인 내부구 조를 가진 고체물질


이런 구조적 특징을 가지려면 분자가 한층 한층 쌓여가는 과정에 의 해 생성되므로 결정의 성장이 상대적으로 느리게 진행된다.

이때 결정의 모양은 결정을 구성하는 분자의 기본적인 구조에 의해 결정된다.









(출처: http://www.its.caltech.edu/~atomic/snowcrystals)



#### 결정화가 일어나는 이유

> 녹을 수 있는 정도(용해도, Solubility)보다 더 많은 용질이 용매에 녹아있을 때 (과포화, Supersaturation), 용질의 분자가 서로 결 합하여 결정을 형성한다.

#### • 과포화의 원인

- > Temperature: 냉각, 용용
- > Concentration: 증발
- Anti-solvent: Drowning-out
- > Additives: 염석
- ▶ Pressure: 진공 (증발+냉각)
- ≻ Reaction: 반응
- > Etc.






# • 결정화의 장점

> 저 에너지 사용


• 전통적인 분리공정에 비해 30~50% 정도의 에너지만 사용

#### ▶ 단일공정


- 공정의 구성이 간단하고 장비가 저렴














# • 증류와 결정화의 비교

| Distillation                                      | Crystallization  |
|---|--|
| PI  | hase equilibria  |
| Both liquid and vapor phases are totally miscible | Liquid phase is totally miscible; solid phases are<br>immiscible |
| Liquid-vapor equilibrium                          | Solid-liquid equilibrium   |
| Neither phase is pure                             | Solid phase is pure  |
| Separation factor is moderate                     | Partition coefficients are very high                             |
| Ultra-high purity is difficult to achieve         | Ultra-high purity is easy to achieve                             |
| No theoretical limit on recovery                  | Recovery is limited by SLE                                       |
| Mass  | transfer kinetics  |
| High mass transfer rate in both VL phases         | Moderate mass transfer rate in liquid and zero in solid          |
| Close approach to equilibrium                     | Slow approach to equilibrium                                     |
| Adiabatic contact assures phase equilibrium       | Solid phase is not in equilibrium                                |
| Pha   | ase separability   |
| Viscosity in both phases is low                   | Liquid phase viscosity is moderate and solid phase rigid         |
| Phase separation is rapid and complete            | Phase separation is slow   |
| Counter current contacting is quick and efficient | Counter current contacting is slow and inefficient               |



# 냉각결정화의 기본 이론








# • 냉각결정화

- ▶ 용액을 온도를 변화시켜 과포화를 유도하여 결정을 생산
- ▶ 온도에 따른 용해도의 변화가 큰 물질에 대해 적용
- ▶ 초기 포화온도를 높일 수 없는 경우는 진공도 사용
  - 고순도이면서 균일한 분포의 생성물을 얻는데 유리
  - 정밀화학 및 반도체 공정에서 많이 사용
  - 품질요소: mean particle size, PSD, morphology, purity






# States of Solution

- 안정영역 (Stable region)
  - > No crystallization or precipitation
  - Nuclei < critical size</p>
  - Nuclei forms and melts in equilibrium
- 불안정영역 (Labile region)
  - Nuclei > critical size
  - Nuclei do not melt back to solution
  - Simultaneous
    - Nuclei formation
    - Crystal growth
- 준안정영역 (Metastable region)
  - No nuclei (larger than critical size) formation
  - Only Crystal growth
  - Very important region for industrial crystallization
    - Controls the particle size distribution and mean particle size

0,00

olecules

Almost no by-product



Embrvos




Process System Engineering Lab., Dept. of Chemical and Biological Engineering, Korea University


Irrversible

Crystals

Nuclei










#### 결정화 조업조건의 중요성

- Inappropriate cooling strategy causes
  - Uneven particle size distribution
  - Smaller mean particle size
- Low purity and low product quality
- Requires time and energy for washing final product





# **Nucleation and Crystal Growth**

#### 핵생성 (Nucleation)

- > 일차핵생성 (Primary nucleation)
  - 균일 핵생성 (Homogeneous nucleation)
    - Solute molecule combines to produce embryos
  - 불균일 핵생성 (Heterogeneous nucleation)
    - ✓ Due to foreign nuclei which has lower surface energy
- 이차핵생성 (Secondary nucleation)
  - Due to solute particles or Seeds
  - Apparent secondary nucleation
    - Small fragments washed from the surface of the seeds
  - True secondary nucleation
    - Current level of supersaturation is higher than the critical level for the solute particles present in solution
  - Contact secondary nucleation
    - Growing particle contacts with walls, stirrer, pump impeller, or other particle and generates residual solute particles

#### 결정의 성장은 주로 degree of supersaturation에 의해 결정



# Supersaturation

- > Thermodynamically, solute in excess of solubility
  - Supersaturation =  $\Delta \mu / RT$  where  $\mu$  is chemical potential

#### For practical use

- $\Delta c = c c^*$  or  $S = c/c^*$  where  $c^*$  is saturation concentration
- Supersaturation ∆c is sometimes called "concentration driving force."



#### Crystallization Kinetics

Nucleation rate: rate of formation of new crystal

$$\frac{dN}{dt} = B = k_N (\Delta c)^b \quad (\text{nuclei/sec} \cdot \text{m}^3)$$

- Where b= order of nucleation
- B=nucleation rate (rate of increase of crystal number)
- Crystal growth: rate of increase of crystal dimension

$$\frac{dL}{dt} = G = k_G (\Delta c)^g \quad \text{(m/sec)}$$

Where b= order of nucleation


B=nucleation rate (rate of increase of crystal number)

#### Crystal agglomeration and breakage are also function of supersaturation



# Metastable Zone Width

● 준안정영역에 관한 정보는 결정화 조업에 매우 중요 ▶ 균일한 PSD에 큰 영향



- Metastable zone width (MZW)
  - > Maximum Allowable Undercooling (MAUC):  $\Delta T_{max}(C)$
  - > Maximum allowable supersaturation (MASS):  $\Delta C_{max}(T)$
- 균일한 PSD를 위한 조업 조건
  > Driving force: ΔC=C-C\*(T) 또는 ΔT=T-T\*(C)
  > 핵생성 조건: ΔC> ΔC<sub>max</sub>(T) 또는 ΔT> ΔT<sub>max</sub>(C)
  > 결정성장은 ΔC나 ΔT (Driving force)가 클수록 빠름



# 조안정영역에 영향을 미치는 인자

> 냉각속도

- 일반적으로 냉각속도가 커질수록 MZW가 커짐

> Agitation

- 교반속도가 너무 느린 영역에서는 변화 없음

일반적으로 교반속도가 커질수록 MZW가 작아짐


> Additives

• 종류에 따라 매우 달라짐

Solution thermal history


- 영향이 있음은 관찰되고 있으나 어떤 영향을 가지는지는 미지수






#### Weakness of previous approaches

- MZW is considered as a Static property
  - $\Delta T_{max} = k(u)^p$
- Cannot explain Induction time
- Other unrealistic behavior
  - Cooling rate changes from nonzero to zero
  - Sudden start of cooling from equilibrium








# New approach

- MZW is not a static property.
- As cooling rate changes, the metastable limit is separated and converged to saturation curve asymptotically.
- Need to introduce dynamic concept.
  - Simple approach: 1<sup>st</sup> or 2<sup>nd</sup> order dynam
- Induction time can be explained.





# Model for batch cooling crystallization

- The dynamic model of the metastable limit
  - To explain the dynamic behaviour of metastable limit, following 1st order dynamic model can be proposed.

$$\tau \frac{\Delta T_{\max}(t)}{dt} + \Delta T_{\max}(t) = ku(t)^{p}$$

Where, u is the cooling rate of the solution, and Three parameters, k, p, and  $\tau$ , are depend on saturation concentration.

This model has 1st order dynamics of supersaturation with nonlinear output to rate of driving force inducing supersaturation.



#### Experiments for defining dynamic model of metastable limit



Reactor of nucleation experiment

- Experimental procedure
  - 1 Making up solution.
    - $(NH_4)_2SO_4 H_2O$  solution
  - 2 Keeping temperature as initial temperature for 1hr.
    - RPM of magnetic bar : 1100rpm (Max.)
  - 3 Keeping temperature as initial temperature for 30min.
    - RPM of magnetic bar : 400rpm
  - **4** Starting cooling experiment
  - **5 Observing nucleation** 
    - RPM of Strobo scope : 1400 rpm



# Experiment 1-1

# • Finding out parameters for the dynamic model

#### Experimental conditions

- Solution concentration (Saturation temperature)
  ✓ 0.8425(50℃), 0.8263(45℃), 0.8100(40℃)
- Initial temperature : 10°C higher than saturation temperature


- Cooling rates : 30℃/h, 25℃/h, 20℃/h, 15℃/h, 10℃/h

- Expected results
  - Parameters for dynamic model of metastable limit

**√ k, p,** τ



### Parameters for the metastable limit model



 $k = 4.545 e^{0.3195T_s} \times 10^{-9}$  $p = 6.894 - 0.1015T_s$  $\tau = 0.3682 + 0.03572T_s$ 

Estimated parameter from experiment 1-1.

| Concentration<br>[solute kg/solvent kg] | Saturation<br>temperature [°C] | k      | р      | τ      |
|---|--------------------------------|--------|--------|--------|
| 0.8425                                  | 50                             | 0.0395 | 1.7976 | 0.5393 |
| 0.8263                                  | 45                             | 0.0015 | 2.9413 | 0.4883 |
| 0.8100                                  | 40                             | 0.0006 | 3.76   | 0.4720 |



# Experiment 1-2


# Verification of Proposition

#### Experimental condition

- Solution concentration : 0.8425 [solute kg/ solvent kg] (T<sub>s</sub>=50℃)
- Initial temperature : 60 ℃ (10 ℃ higher than saturation temperature)
- Cooling rate : 30℃/h
- Keeping solution temperature at : 43°C, 45°C, 47°C
- Expected results
  - Induction time is well predicted by the dynamic model



# • Prediction of Nucleation time



Simulation result of experiment 1-2.

Results of experiment 1–2.

|     | Nucleation time<br>(Experiment)<br>[sec] | Nucleation time<br>(Simulation)<br>[sec] |
|-----|--|--|
| (a) | 149                                      | 165                                      |
| (b) | 740                                      | 705                                      |
| (c) | 1374                                     | 1404                                     |

linear cooling of  $30^{\circ}$ /h from  $60^{\circ}$  to (a)  $43^{\circ}$ , (b)  $45^{\circ}$ , (c)  $47^{\circ}$  and then hold




# Experiment 1-3

#### Predicting the effect of thermal history

- Experimental condition
  - Solution concentration : 0.8425 [solute kg/ solvent kg]  $(T_s=50^{\circ})$
  - Initial temperature : 55℃ (5℃ higher than saturation temperature)
  - Cooling rate : 30℃/h
  - Different thermal history
    - ✓ Linear cooling from 60 °C to 55 °C. Cooling rate is 30 °C/h
    - ✓ Keeping temperature as 55℃
    - ✓ Linear cooling from 60  $^\circ$  to 55  $^\circ$ . Cooling rate is 5  $^\circ$ /h
    - ✓ Linear cooling from 60°C to 55°C. Cooling rate is 2.5 °C/h
- Expected results
  - Thermo history is well predicted by dynamic model



#### Prediction of Nucleation time for different thermal history



Simulation result of experiment 1-3.



# Thank you!

